ADHESIVE COMPOSITION FOR SOFT TISSUE, ADHESIVE COMPOSITION FOR COVERING WOUNDS, OR WOUND COVERING AGENT COMPOSITION
    42.
    发明公开
    ADHESIVE COMPOSITION FOR SOFT TISSUE, ADHESIVE COMPOSITION FOR COVERING WOUNDS, OR WOUND COVERING AGENT COMPOSITION 有权
    用粘结剂组合物软组织,用粘结剂组合物伤口覆盖物或装置WOUNDS盖组成

    公开(公告)号:EP2502637A1

    公开(公告)日:2012-09-26

    申请号:EP10831607.6

    申请日:2010-11-18

    IPC分类号: A61L24/00 A61L15/16

    摘要: The adhesive composition for soft tissues, the adhesive composition for wound dressing or the wound dressing agent composition of the present invention is an adhesive composition for soft tissues, an adhesive composition for wound dressing or a wound dressing agent composition, comprising a monomer (A), a polymer (B) and a polymerization initiator composition (C) containing an organoboron compound, and is characterized by having a viscosity of 0.4 to 75,000 cp within 30 seconds after mixing of the components (A), (B) and (C). The composition of the present invention not only has low toxicity, low harmfulness and high adhesive strength but also is excellent in workability during application and is capable of forming films of excellent properties.

    摘要翻译: 软组织用粘合剂组合物,伤口敷料或本发明的伤口敷料剂组合物中的粘合剂组合物是用于软组织的粘合剂组合物,粘合剂组合物用于伤口敷料或伤口敷料剂组合物,其包含单体(A) 中,聚合物(B)中,在有机硼化合物含有聚合引发剂组合物,(C),并且通过具有0.4的粘度的组分(A)混合后表征以75000厘泊在30秒内,(B)和(C) , 本发明不仅所述的组合物具有低毒性,低危害性和高粘合强度,但这样是应用期间的可加工性优异并且能够形成优异的特性的膜。

    TREATMENT OF DEPENDENCE WITHDRAWAL
    46.
    发明公开
    TREATMENT OF DEPENDENCE WITHDRAWAL 有权
    治疗戒断

    公开(公告)号:EP1646328A2

    公开(公告)日:2006-04-19

    申请号:EP04779186.8

    申请日:2004-07-26

    IPC分类号: A61B19/00

    摘要: Dosage regimens of buprenorphine to treat withdrawal or abstinence syndrome in a drug dependent or opioid tolerant patient who is pregnant are described. The method includes treating withdrawal or abstinence syndrome of the patient by transdermal administration of an amount of buprenorphine effective to reduce withdrawal symptoms. For example, a first buprenorphine-containing transdermal dosage form can be administered for a first dosing period that is no more than about 5 days; a second buprenorphine-containing transdermal dosage form for a second dosing period that is no more than about 5 days, the second dosage form comprising the same or a greater dosage of buprenorphine than the first dosage form; and a third buprenorphine-containing transdermal dosage form for a third dosing period that is at least 2 days, the third dosage form comprising the same or a greater dosage of buprenorphine than the second dosage form.

    EMULSION COMPOSITIONS
    47.
    发明公开
    EMULSION COMPOSITIONS 审中-公开
    粒子稳定化组合物

    公开(公告)号:EP1487396A1

    公开(公告)日:2004-12-22

    申请号:EP03716850.7

    申请日:2003-03-27

    摘要: The present invention relates to particle stabilizing compositions suitable for use in fabric care products, home care products, diapers, incontinence articles, feminine care products, pharmaceuticals, oral care products, antiperspirants, deodorants, personal cleansing products, skin care products and hair care products comprising: a) an emulsion comprising from about 1% to about 99% by weight of the emulsion of an internal phase and from about 1% to about 99% by weight of the emulsion of an external phase; b) a charged species that is present in the emulsion; and c) charged insoluble solid particles which are dispersed in the emulsion wherein the charged species possesses a charge which is opposed to that of the charged insoluble solid particles and wherein essentially all of the charged species and charged insoluble solid particles accumulate at the interface of the emulsion and wherein Brownian motion is not exhibited by the charged insoluble solid particles.